90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL

NCT00186589 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Non-Hodgkin
Blood and Marrow Transplant (BMT)

Interventions

DRUG: 90Y Ibritumomab tiuxetan

Sponsor

Stanford University

Collaborators

[object Object]
[object Object]